Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
Clinical trial NCT07027111 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07027111
- Sponsor
- Nuvig Therapeutics, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-25
- Primary completion
- 2026-07-31
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.